BiotechReporter.news – Vertex Pharmaceuticals (VRTX:NASDAQ) is trading at record highs following expanded regulatory approvals for its cystic fibrosis therapy TRIKAFTA. The drug is now approved for use in younger pediatric populations, significantly increasing Vertex’s addressable market. Q3 earnings exceeded expectations, with CF revenues driving a 12% year-over-year increase. Beyond cystic fibrosis, Vertex is advancing late-stage programs in sickle cell disease and type 1 diabetes, reinforcing its pipeline depth. Analysts cite Vertex’s consistent execution and durable revenue streams as standout traits in a volatile biotech sector. With strong fundamentals and expanding therapeutic reach, Vertex remains a top-tier performer in the industry.
61
